Sökning: WFRF:(O'Doherty M. G.) >
Multicenter Reprodu...
Multicenter Reproducibility of F-18-Fluciclatide PET Imaging in Subjects with Solid Tumors
-
- Sharma, Rohini (författare)
- Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Expt Med, London W12 0NN, England.
-
- Kallur, Kumar G. (författare)
- HCG, PETCT, Bangalore, Karnataka, India.;HCG, Cyclotron Dept, Bangalore, Karnataka, India.
-
- Ryu, Jin S. (författare)
- Asan Med Ctr, Dept Nucl Med, Seoul, South Korea.
-
visa fler...
-
- Parameswaran, Ramanathapuram V. (författare)
- Manipal Hosp, Dept Nucl Med, Bangalore, Karnataka, India.;Manipal Hosp, PET CT Div, Bangalore, Karnataka, India.
-
- Lindman, Henrik (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Avril, Norbert (författare)
- Queen Mary Univ London, Barts Hlth, Dept Nucl Med, London, England.
-
- Gleeson, Fergus V. (författare)
- Oxford Radcliffe Hosp Trust, Churchill Hosp, Dept Radiol, Oxford, England.
-
- Lee, Jong D. (författare)
- Yonsei Univ Hlth Syst, Dept Nucl Med, Seoul, South Korea.
-
- Lee, Kyung-Han (författare)
- Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Nucl Med, Seoul, South Korea.
-
- O'Doherty, Michael J. (författare)
- Kings Coll London, Div Imaging Sci & Biomed Engn, PET Imaging Ctr, London WC2R 2LS, England.
-
- Groves, Ashley M. (författare)
- UCL, Inst Nucl Med, London, England.
-
- Miller, Matthew P. (författare)
- GE Healthcare Life Sci, Imaging R&D, Amersham, England.
-
- Somer, Edward J. (författare)
- GE Healthcare Life Sci, Imaging R&D, Amersham, England.
-
- Coombes, Charles R. (författare)
- Univ London Imperial Coll Sci Technol & Med, Fac Med, Hammersmith Hosp, Dept Surg & Canc, London, England.
-
- Aboagye, Eric O. (författare)
- Univ London Imperial Coll Sci Technol & Med, Fac Med, Hammersmith Hosp, Dept Surg & Canc, London, England.
-
visa färre...
-
Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Expt Med, London W12 0NN, England HCG, PETCT, Bangalore, Karnataka, India.;HCG, Cyclotron Dept, Bangalore, Karnataka, India. (creator_code:org_t)
- 2015-09-17
- 2015
- Engelska.
-
Ingår i: Journal of Nuclear Medicine. - : Society of Nuclear Medicine. - 0161-5505 .- 1535-5667 .- 2159-662X. ; 56:12, s. 1855-1861
- Relaterad länk:
-
http://jnm.snmjourna...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- Integrins are upregulated on both tumor cells and associated vasculature, where they play an important role in angiogenesis and metastasis. Fluciclatide is an arginine-glycine-aspartic acid peptide with high affinity for alpha(v)beta(3)/alpha(v)beta(5) integrin, which can be radio-labeled for PET imaging of angiogenesis. Thus, F-18-fluciclatide is a potential biomarker of therapeutic response to antiangiogenic inhibitors. The aim of this study was to evaluate the reproducibility of F-18-fluciclatide in multiple solid-tumor types. Methods: Thirty-nine patients underwent PET/CT scanning at 40, 65, and 90 min after injection of F-18-fluciclatide (maximum, 370 MBq) on 2 separate days (2-9 d apart). Patients did not receive any therapy between PET/CT scans. F-18-fluciclatide images were reported and quantitative measures of uptake were extracted using the PERCIST methodology. Intrasubject reproducibility of PET uptake in all measurable lesions was evaluated by calculating relative differences in SUV between PET scans for each lesion during the 2 imaging sessions. Results: Thirty-nine measurable lesions were detected in 26 patients. Lesion uptake correlated strongly across imaging sessions (r = 0.92, P < 0.05, at 40 min; r = 0.94, P < 0.05, at 65 min; r = 0.94, P, 0.05, at 90 min) with a mean relative difference and SD of the relative difference of 0.006 +/- 0.18 at 40 min, 0.003 +/- 0.19 at 65 min, and 0.025 +/- 0.20 at 90 min. This reflects 95% limits of repeatability of 35%-39% for the difference between the 2 SUV measurements or a variability of 18%-20% in agreement from that observed in well-calibrated multicenter F-18-FDG studies. Conclusion: The test-retest reproducibility of F-18-fluciclatide across multiple tumor types has been measured and shown to be acceptable. This is an important step in the development of this in vivo biomarker to identify and quantify response to antiangiogenic therapy in cancer patients.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Nyckelord
- reproducibility
- F-18-fluciclatide
- cancer
- angiogenesis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sharma, Rohini
-
Kallur, Kumar G.
-
Ryu, Jin S.
-
Parameswaran, Ra ...
-
Lindman, Henrik
-
Avril, Norbert
-
visa fler...
-
Gleeson, Fergus ...
-
Lee, Jong D.
-
Lee, Kyung-Han
-
O'Doherty, Micha ...
-
Groves, Ashley M ...
-
Miller, Matthew ...
-
Somer, Edward J.
-
Coombes, Charles ...
-
Aboagye, Eric O.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Radiologi och bi ...
- Artiklar i publikationen
-
Journal of Nucle ...
- Av lärosätet
-
Uppsala universitet